EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy and tolerability of perampanel as add‐on therapy in Dravet syndrome: A prospective real‐world study

Han Wang iD, Hong Chen iD, Xin Ding, Xueyan Cao, Jiahui Mai, Huafang Zou iD, Dongfang Zou iD, Yanwei Zhu, Jianxiang Liao, Dezhi Cao iD

Epilepsia Open · 2025

DOI: 10.1002/epi4.70058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia Open, 2025. Verfasst von Han Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Shenzhen Children's Hospital, Shenzhen, China. Hauptthemen laut MEDLINE: Nitriles, Epilepsies, Myoclonic, Anticonvulsants, Pyridones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanming Project of Medicine in Shenzhen, Basic Research of Shenzhen Science and Technology Plan Project, Guangdong High-level Hospital Construction Fund Clinical Research Project of Shenzhen Children's Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the efficacy and tolerability of perampanel (PER) on Dravet syndrome in China by a prospective real‐world study.

Methods

We prospectively enrolled children with Dravet syndrome from the neurology clinic of Shenzhen Children's Hospital from September 2020 to October 2021. The average monthly seizure frequency within 2 months before enrollment was recorded as the baseline. PER was administered after enrollment. The response rate (the rate of seizure reduction ≥50% compared to the baseline) was regarded as the major index. The adverse events and retention rates were regarded as the minor index. All indexes were calculated after 3 and 6 months' follow‐up, respectively. The outcome‐predictive value of various clinical factors was analyzed.

Results

A total of 21 children were enrolled, including 15 boys and 6 girls, with a median age of 4 years and 8 months (1 year and 3 months to 15 years and 6 months). Averagely, 2.57 ASMs had been administrated and failed to control seizures before enrollment. The response rates were 52.4% (11/21) and 47.6% (10/21) after 3 and 6 months of PER administration, respectively. Adverse events were observed in 8 patients (38.1%), including irritability (3/8, 37.5%), fatigue (3/8, 37.5%), unstable walking (2/8, 25%), somnolence (2/8, 25%), and sluggish response (2/8, 25%); most of them were mild and temporary. The retention rate was 90.5% (19/21) at 6 months' follow‐up. Two patients discontinued PER due to failure of seizure control, and no patients discontinued due to adverse events. Significance This study provides a comprehensive analysis of PER's effectiveness and tolerability in treating DS, highlighting its importance as an additional treatment option. It broadens the range of anti‐seizure medications (ASMs) that may be effective for patients with DS. Plain Language Summary In the neurology clinic of Shenzhen Children's Hospital, 21 children with Dravet syndrome were administered perampanel. Perampanel, as a novel anti‐seizure medication approved for focal and generalized epilepsies as add‐on therapy, showed sufficient efficacy and a satisfactory safety and tolerability profile in this study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NitrilesEpilepsies, MyoclonicAnticonvulsantsPyridonesHumansMaleFemaleChild, PreschoolChildProspective StudiesAdolescentInfantTreatment OutcomeDrug Therapy, Combination

Stichwörter der Autor:innen

ChinaDravet syndromeSCN1A geneefficacyperampanel

Substanzen

perampanelNitrilesAnticonvulsantsPyridones

Autor:innen und Institutionen

  • Department of Neurology, Shenzhen Children's Hospital, Shenzhen, China.

ORCID-Profile: Han Wang, Hong Chen, Huafang Zou, Dongfang Zou, Dezhi Cao

Förderung

  • Sanming Project of Medicine in Shenzhen
  • Basic Research of Shenzhen Science and Technology Plan Project
  • Guangdong High-level Hospital Construction Fund Clinical Research Project of Shenzhen Children's Hospital
  • Sanming Project of Medicine in Shenzen Municipality

Zitieren

APA

Wang, H., Chen, H., Ding, X., Cao, X., Mai, J., Zou, H., Zou, D., Zhu, Y., Liao, J., & Cao, D. (2025). Efficacy and tolerability of perampanel as add‐on therapy in Dravet syndrome: A prospective real‐world study. Epilepsia Open. https://doi.org/10.1002/epi4.70058

Vancouver

Wang H, Chen H, Ding X, Cao X, Mai J, Zou H, et al. Efficacy and tolerability of perampanel as add‐on therapy in Dravet syndrome: A prospective real‐world study. Epilepsia Open. 2025. doi:10.1002/epi4.70058

BibTeX
@article{Wang2025,
  author = {Wang, Han and Chen, Hong and Ding, Xin and Cao, Xueyan and Mai, Jiahui and Zou, Huafang and Zou, Dongfang and Zhu, Yanwei and Liao, Jianxiang and Cao, Dezhi},
  title = {Efficacy and tolerability of perampanel as add‐on therapy in Dravet syndrome: A prospective real‐world study},
  journal = {Epilepsia Open},
  year = {2025},
  doi = {10.1002/epi4.70058}
}
Kostenlos starten →